Protara Therapeutics (TARA) CEO has 8,732 shares withheld for taxes

Rhea-AI Filing Summary

Protara Therapeutics CEO and President Jesse Shefferman, a director of Protara Therapeutics, Inc. (TARA), reported a routine share withholding related to equity compensation. On January 26, 2026, the company withheld 8,732 shares of common stock at $6.67 per share to cover income tax obligations tied to the vesting of a restricted stock unit award granted on January 24, 2025. After this tax withholding, Shefferman beneficially owns 1,021,832 shares of Protara common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shefferman Jesse

Role CEO and President

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	8,732	$6.67	$58K

Holdings After Transaction: Common Stock — 1,021,832 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shefferman Jesse

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		F		8,732(1)	D	$6.67	1,021,832	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 24, 2025.

Remarks:

	/s/ Jesse Shefferman	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Protara Therapeutics (TARA) report for Jesse Shefferman?

Protara Therapeutics reported that CEO and President Jesse Shefferman had 8,732 shares of common stock withheld on January 26, 2026 to cover income tax obligations from a vested restricted stock unit award.

Was the Protara Therapeutics (TARA) insider transaction a sale in the open market?

No. The filing shows an F-code transaction, which represents shares withheld by the issuer to satisfy tax obligations upon vesting of a restricted stock unit award, rather than an open-market sale.

How many Protara Therapeutics (TARA) shares does Jesse Shefferman own after this transaction?

Following the reported tax withholding, Jesse Shefferman beneficially owns 1,021,832 shares of Protara Therapeutics common stock, held directly.

What is the price associated with the withheld Protara Therapeutics (TARA) shares?

The 8,732 withheld shares of Protara Therapeutics common stock are reported at a price of $6.67 per share for the tax withholding transaction.

What is the origin of the equity underlying this Protara Therapeutics (TARA) Form 4 transaction?

The shares withheld relate to the vesting of a Restricted Stock Unit Award that was granted to Jesse Shefferman on January 24, 2025, as stated in the filing footnote.

What is Jesse Shefferman’s role at Protara Therapeutics (TARA)?

According to the filing, Jesse Shefferman is a director and serves as CEO and President of Protara Therapeutics, Inc.